FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062251909> ?p ?o ?g. }

• W2062251909 endingPage "234" @default.
• W2062251909 startingPage "227" @default.
• W2062251909 abstract "Introduction:After decades of research, pancreatic cancer is still a devastating disease. The aim of this article was to assess the efficacy and safety of combination chemotherapy with gemcitabine (GEM) and S-1 (GS) therapy compared with GEM alone therapy in patients with locally advanced or metastatic pancreatic cancer.Methods:Relevant trials were identified by searching databases. Five trials were selected in this article. The indicators we used were overall response rate, disease control rate, 1-year survival rate and haematological toxicities.Results:Meta-analysis of the pooled data demonstrated that the overall response rate (risk ratio, RR = 2.52, 95% confidence interval, CI: 1.85–3.42, P < 0.00001) and disease control rate (RR = 1.24, 95% CI: 1.12–1.37, P < 0.0001) were significantly different for the GS and GEM alone chemotherapies. Among the group of patients, 43.4% in the GS group and 31.4% in the GEM group survived more than a year. According to this, patients who use the GS regiment may have a better prognosis than the GEM regiment (RR = 1.62, 95% CI: 1.12–2.33, P = 0.04). The combination chemotherapy with GEM and S-1 group had higher haematological toxicities including neutropaenia (RR = 1.58, 95% CI: 1.17–2.14, P = 0.003) and thrombocytopaenia (RR = 1.85, 95% CI: 1.28–2.67, P = 0.001). The incidence of anaemia was much the same in the two groups (RR = 1.22, 95% CI: 0.87–1.70, P = 0.24).Discussion:Overall response rate and disease control rate as well as 1-year survival rate in patients who received GS were superior to those treated with GEM alone. Combination chemotherapy with GEM and S-1 may offer greater benefits in the treatment of pancreatic cancer than GEM alone, although the GS group had higher haematological toxicities. Combination chemotherapy with GEM and S-1 might be an option of first-line chemotherapy for pancreatic cancer patients, at least in Asia.Mini Abstract: This systematic review analysing randomized controlled trials (RCTs) comparing S-1 combination chemotherapy versus GEM alone for locally advanced and metastatic pancreatic cancer demonstrated greater efficacy for S-1 combination in term of response, disease control and 1-year survival proportion." @default.
• W2062251909 created "2016-06-24" @default.
• W2062251909 creator A5040197406 @default.
• W2062251909 creator A5045257827 @default.
• W2062251909 creator A5074153790 @default.
• W2062251909 creator A5076410909 @default.
• W2062251909 creator A5086485895 @default.
• W2062251909 date "2015-03-20" @default.
• W2062251909 modified "2023-09-23" @default.
• W2062251909 title "Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia" @default.
• W2062251909 cites W1931508686 @default.
• W2062251909 cites W1970238406 @default.
• W2062251909 cites W1972107936 @default.
• W2062251909 cites W1973173224 @default.
• W2062251909 cites W1975243149 @default.
• W2062251909 cites W1988033486 @default.
• W2062251909 cites W1995709092 @default.
• W2062251909 cites W2006200497 @default.
• W2062251909 cites W2019490988 @default.
• W2062251909 cites W2024826853 @default.
• W2062251909 cites W2046997258 @default.
• W2062251909 cites W2054758921 @default.
• W2062251909 cites W2067379301 @default.
• W2062251909 cites W2077902459 @default.
• W2062251909 cites W2079418758 @default.
• W2062251909 cites W2082398974 @default.
• W2062251909 cites W2095997161 @default.
• W2062251909 cites W2098923148 @default.
• W2062251909 cites W2103711657 @default.
• W2062251909 cites W2113566724 @default.
• W2062251909 cites W2121933347 @default.
• W2062251909 cites W2131481746 @default.
• W2062251909 cites W2143953275 @default.
• W2062251909 cites W2145534346 @default.
• W2062251909 cites W2161147823 @default.
• W2062251909 cites W2172089182 @default.
• W2062251909 cites W4238493616 @default.
• W2062251909 doi "https://doi.org/10.1179/1973947815y.0000000013" @default.
• W2062251909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25790948" @default.
• W2062251909 hasPublicationYear "2015" @default.
• W2062251909 type Work @default.
• W2062251909 sameAs 2062251909 @default.
• W2062251909 citedByCount "13" @default.
• W2062251909 countsByYear W20622519092015 @default.
• W2062251909 countsByYear W20622519092016 @default.
• W2062251909 countsByYear W20622519092017 @default.
• W2062251909 countsByYear W20622519092018 @default.
• W2062251909 countsByYear W20622519092019 @default.
• W2062251909 countsByYear W20622519092020 @default.
• W2062251909 countsByYear W20622519092021 @default.
• W2062251909 crossrefType "journal-article" @default.
• W2062251909 hasAuthorship W2062251909A5040197406 @default.
• W2062251909 hasAuthorship W2062251909A5045257827 @default.
• W2062251909 hasAuthorship W2062251909A5074153790 @default.
• W2062251909 hasAuthorship W2062251909A5076410909 @default.
• W2062251909 hasAuthorship W2062251909A5086485895 @default.
• W2062251909 hasConcept C120665830 @default.
• W2062251909 hasConcept C121332964 @default.
• W2062251909 hasConcept C121608353 @default.
• W2062251909 hasConcept C126322002 @default.
• W2062251909 hasConcept C143998085 @default.
• W2062251909 hasConcept C167704817 @default.
• W2062251909 hasConcept C168563851 @default.
• W2062251909 hasConcept C2776694085 @default.
• W2062251909 hasConcept C2780210213 @default.
• W2062251909 hasConcept C2780258809 @default.
• W2062251909 hasConcept C44249647 @default.
• W2062251909 hasConcept C61511704 @default.
• W2062251909 hasConcept C71924100 @default.
• W2062251909 hasConcept C82789193 @default.
• W2062251909 hasConcept C90924648 @default.
• W2062251909 hasConcept C95190672 @default.
• W2062251909 hasConceptScore W2062251909C120665830 @default.
• W2062251909 hasConceptScore W2062251909C121332964 @default.
• W2062251909 hasConceptScore W2062251909C121608353 @default.
• W2062251909 hasConceptScore W2062251909C126322002 @default.
• W2062251909 hasConceptScore W2062251909C143998085 @default.
• W2062251909 hasConceptScore W2062251909C167704817 @default.
• W2062251909 hasConceptScore W2062251909C168563851 @default.
• W2062251909 hasConceptScore W2062251909C2776694085 @default.
• W2062251909 hasConceptScore W2062251909C2780210213 @default.
• W2062251909 hasConceptScore W2062251909C2780258809 @default.
• W2062251909 hasConceptScore W2062251909C44249647 @default.
• W2062251909 hasConceptScore W2062251909C61511704 @default.
• W2062251909 hasConceptScore W2062251909C71924100 @default.
• W2062251909 hasConceptScore W2062251909C82789193 @default.
• W2062251909 hasConceptScore W2062251909C90924648 @default.
• W2062251909 hasConceptScore W2062251909C95190672 @default.
• W2062251909 hasIssue "4" @default.
• W2062251909 hasLocation W20622519091 @default.
• W2062251909 hasLocation W20622519092 @default.
• W2062251909 hasOpenAccess W2062251909 @default.
• W2062251909 hasPrimaryLocation W20622519091 @default.
• W2062251909 hasRelatedWork W1969578744 @default.
• W2062251909 hasRelatedWork W2005537476 @default.
• W2062251909 hasRelatedWork W2319496893 @default.
• W2062251909 hasRelatedWork W2349340765 @default.
• W2062251909 hasRelatedWork W2365966720 @default.

• next